A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) (NCT05506943)
A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen
🩺 Plain-English Summary (8th-Grade Level)
This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Arizona — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (34 Sites)
Showing the first 25 of 34 sites.
- Mayo Clinic Arizona — Phoenix, Arizona
- University of Arizona — Tucson, Arizona
- University of Southern California Norris Comprehensive Cancer Center — Los Angeles, California
- Stanford Medicine Cancer Center — Palo Alto, California
- University of California San Francisco — San Francisco, California
- Rocky Mountain Cancer Centers, LLP — Aurora, Colorado
- University of Florida — Gainesville, Florida
- Mayo Clinic Jacksonville — Jacksonville, Florida
- AdventHealth Orlando — Orlando, Florida
- Northwestern University — Chicago, Illinois
- University of Chicago — Chicago, Illinois
- Ochsner Clinic Foundation — New Orleans, Louisiana
- Johns Hopkins University — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Mayo Clinic Rochester — Rochester, Minnesota
- Washington University School of Medicine, Siteman Cancer Center — St Louis, Missouri
- Rutgers Cancer Institute — New Brunswick, New Jersey
- The University of New Mexico — Albuquerque, New Mexico
- Memorial Medical Center — Las Cruces, New Mexico
- Roswell Park — Buffalo, New York
- Columbia University — New York, New York
- Montefiore Medical Center — The Bronx, New York
- Gabrail Cancer Center — Canton, Ohio
- Cleveland Clinic — Cleveland, Ohio
- University of Tennessee Medical Center — Knoxville, Tennessee
📞 Contact the Study Coordinator
Phone: (800) 664-4580
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Biliary Tract Cancer
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers — Pittsburgh, Pennsylvania
- Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) — Birmingham, Alabama
- A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer — Tucson, Arizona
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) — Mobile, Alabama
- XmAb20717 in Advanced Biliary Tract Cancers — Philadelphia, Pennsylvania
Explore by condition: All Biliary Tract Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.